Delivery of the Report will take 2-3 working days once order is placed.
DelveInsight's Hepatitis D - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Hepatitis D in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
- China
Study Period: 2016-2028
Hepatitis D Epidemiology
The Hepatitis D epidemiology division provide the insights about historical and current patient pool and forecasted trend for each of the 8 major countries. The epidemiology data for Hepatitis D are studied through all possible division to give a better understanding about the Disease scenario in 8MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Hepatitis D Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, prevalence by Severity (Fulminant, Acute & Chronic), Gender Specific prevalence, Age Specific prevalence and diagnosed cases] of Hepatitis D in the 8MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2028.
The DelveInsight report also provides the epidemiology trends observed in the 8MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, total prevalent population of Hepatitis D in 8 major markets was estimated to be 10,546,938 in 2016.
Report Scope
- The report covers detailed overview of Hepatitis D explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The report provides the insight about the historical and forecasted patient pool of Hepatitis D in 8 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan and China.
- The Report assesses the disease risk and burden and highlights the unmet needs of the disease
- The Report helps to recognize the growth opportunities in the 8MM with respect to the patient population
- The report provides the segmentation of the disease epidemiology by severity (Fulminant, Acute & Chronic), Gender-Specific, Age-specific and diagnosed prevalent cases of Hepatitis D
Key strengths
- 10 Year Forecast of Hepatitis D epidemiology
- 8MM Coverage
- Diagnosed Prevalent cases of Hepatitis D
- Prevalent Cases according to segmentation: by severity (Fulminant, Acute & Chronic), Gender-Specific, Age-specific and diagnosed prevalent cases of Hepatitis D in 8MM
Key assessments
- Patient Segmentation
- Disease Risk & Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Hepatitis D - Epidemiology Forecast to 2028
Table of Contents
1. Key Insights
2. Disease Background and Overview: Hepatitis D
2.1. Introduction
2.2. Classification
2.3. Factors influencing Hepatitis D Progression
2.4. Disease Causes
2.5. HDV-Symptoms
2.6. Pathogenesis
2.7. Pathophysiology
2.8. HDV Diagnosis
2.9. Prevention
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. 8MM Prevalent Population of Hepatitis D
4. Country Wise-Epidemiology of Hepatitis D
4.1. United States
4.1.1. Prevalent cases of Hepatitis D in the United States
4.1.2. Prevalent Population of Hepatitis D by severity
4.1.3. Gender Specific Hepatitis D Prevalence
4.1.4. Age Specific Hepatitis D Prevalence
4.1.5. Diagnosed cases of Chronic Hepatitis D
4.2. EU5
4.2.1. Prevalent Population of Hepatitis D in EU5
4.3. France
4.3.1. Prevalent Population of Hepatitis D
4.3.2. Prevalent Population of Hepatitis D by severity
4.3.3. Gender Specific Hepatitis D Prevalence
4.3.4. Age Specific Hepatitis D Prevalence
4.3.5. Diagnosed cases of Chronic Hepatitis D
4.4. Germany
4.4.1. Prevalent Population of Hepatitis D
4.4.2. Prevalent Population of Hepatitis D by severity
4.4.3. Gender Specific Hepatitis D Prevalence
4.4.4. Age Specific Hepatitis D Prevalence
4.4.5. Diagnosed cases of Chronic Hepatitis D
4.5. Italy
4.5.1. Prevalent Population of Hepatitis D
4.5.2. Prevalent Population of Hepatitis D by severity
4.5.3. Gender Specific Hepatitis D Prevalence
4.5.4. Age Specific Hepatitis D Prevalence
4.5.5. Diagnosed cases of Chronic Hepatitis D
4.6. Spain
4.6.1. Prevalent Population of Hepatitis D
4.6.2. Prevalent Population of Hepatitis D by severity
4.6.3. Gender Specific Hepatitis D Prevalence
4.6.4. Age Specific Hepatitis D Prevalence
4.6.5. Diagnosed cases of Chronic Hepatitis D
4.7. United Kingdom
4.7.1. Prevalent Population of Hepatitis D
4.7.2. Prevalent Population of Hepatitis D by severity
4.7.3. Gender Specific Hepatitis D Prevalence
4.7.4. Age Specific Hepatitis D Prevalence
4.7.5. Diagnosed cases of Chronic Hepatitis D
4.8. Japan
4.8.1. Prevalent Population of Hepatitis D
4.8.2. Prevalent Population of Hepatitis D by severity
4.8.3. Gender Specific Hepatitis D Prevalence
4.8.4. Age Specific Hepatitis D Prevalence
4.8.5. Diagnosed cases of Chronic Hepatitis D
4.9. China
4.9.1. Prevalent Population of Hepatitis D
4.9.2. Prevalent Population of Hepatitis D by severity
4.9.3. Gender Specific Hepatitis D Prevalence
4.9.4. Age Specific Hepatitis D Prevalence
4.9.5. Diagnosed cases of Chronic Hepatitis D
5. Appendix
6. Report Methodology
6.1. Sources Used
7. DelveInsight Capabilities
8. Disclaimer
9. About DelveInsight
List of Tables
Table 1: 8MM, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Table 2: The United States, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Table 3: The United States, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Table 4: The United States, Gender-Specific Hepatitis D Prevalence, 2016-2028
Table 5: The United States, Age-Specific Hepatitis D Prevalence, 2016-2028
Table 6: The United States, Diagnosed cases of Hepatitis D, 2016-2028
Table 7: EU5, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Table 8: France, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Table 9: France, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Table 10: France, Gender Specific Hepatitis D Prevalence, 2016-2028
Table 11: France, Age Specific Hepatitis D Prevalence, 2016-2028
Table 12: France, Diagnosed cases of Hepatitis D, 2016-2028
Table 13: Germany, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Table 14: Germany, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Table 15: Germany, Gender-Specific Hepatitis D Prevalence, 2016-2028
Table 16: Germany, Age-Specific Hepatitis D Prevalence, 2016-2028
Table 17: Germany, Diagnosed cases of Hepatitis D, 2016-2028
Table 18: Italy, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Table 19: Italy, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Table 20: Italy, Gender-Specific Hepatitis D Prevalence, 2016-2028
Table 21: Italy, Age-Specific Hepatitis D Prevalence, 2016-2028
Table 22: Italy, Diagnosed cases of Hepatitis D, 2016-2028
Table 23: Spain, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Table 24: Spain, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Table 25: Spain, Gender Specific Hepatitis D Prevalence, 2016-2028
Table 26: Spain, Age Specific Hepatitis D Prevalence, 2016-2028
Table 27: Spain, Diagnosed cases of Hepatitis D, 2016-2028
Table 28: The United Kingdom, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Table 29: The United Kingdom, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Table 30: The United Kingdom, Gender Specific Hepatitis D Prevalence, 2016-2028
Table 31: The United Kingdom, Age-Specific Hepatitis D Prevalence, 2016-2028
Table 32: The United Kingdom, Diagnosed cases of Hepatitis D, 2016-2028
Table 33: Japan, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Table 34: Japan, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Table 35: Japan, Gender Specific Hepatitis D Prevalence, 2016-2028
Table 36: Japan, Age Specific Hepatitis D Prevalence, 2016-2028
Table 37: Japan, Diagnosed cases of Hepatitis D, 2016-2028
Table 38: China, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Table 39: China, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Table 40: China, Gender Specific Hepatitis D Prevalence, 2016-2028
Table 41: China, Age Specific Hepatitis D Prevalence, 2016-2028
Table 42: China, Diagnosed cases of Hepatitis D, 2016-2028
List of Figures
Figure 1: Hepatitis Delta Virus Structure
Figure 2: Pathogenesis of Hepatitis D
Figure 3: Diagnostic markers in various hepatitis D disease patterns
Figure 4: 8MM, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Figure 5: The United States, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Figure 6: The United States, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Figure 7: The United States, Gender-Specific Hepatitis D Prevalence, 2016-2028
Figure 8: The United States, Age Specific Hepatitis D Prevalence, 2016-2028
Figure 9: The United States, Diagnosed cases of Hepatitis D, 2016-2028
Figure 10: EU5, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Figure 11: France, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Figure 12: France, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Figure 13: France, Gender Specific Hepatitis D Prevalence, 2016-2028
Figure 14: France, Age-specific Hepatitis D Prevalence, 2016-2028
Figure 15: France, Diagnosed cases of Hepatitis D, 2016-2028
Figure 16: Germany, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Figure 17: Germany, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Figure 18: Germany, Gender-Specific Hepatitis D Prevalence, 2016-2028
Figure 19: Germany, Age-Specific Hepatitis D Prevalence, 2016-2028
Figure 20: Germany, Diagnosed cases of Hepatitis D, 2016-2028
Figure 21: Italy, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Figure 22: Italy, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Figure 23: Italy, Gender-Specific Hepatitis D Prevalence, 2016-2028
Figure 24: Italy, Age-Specific Hepatitis D Prevalence, 2016-2028
Figure 25: Italy, Diagnosed cases of Hepatitis D, 2016-2028
Figure 26: Spain, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Figure 27: Spain, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Figure 28: Spain, Gender Specific Hepatitis D Prevalence, 2016-2028
Figure 29: Spain, Age Specific Hepatitis D Prevalence, 2016-2028
Figure 30: Spain, Diagnosed cases of Hepatitis D, 2016-2028
Figure 31: The United Kingdom, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Figure 32: The United Kingdom, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Figure 33: The United Kingdom, Gender-Specific Hepatitis D Prevalence, 2016-2028
Figure 34: The United Kingdom, Age Specific Hepatitis D Prevalence, 2016-2028
Figure 35: The United Kingdom, Diagnosed cases of Hepatitis D, 2016-2028
Figure 36: Japan, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Figure 37: Japan, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Figure 38: Japan, Gender Specific Hepatitis D Prevalence, 2016-2028
Figure 39: Japan, Age Specific Hepatitis D Prevalence, 2016-2028
Figure 40: Japan, Diagnosed cases of Hepatitis D, 2016-2028
Figure 41: China, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
Figure 42: China, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
Figure 43: China, Gender Specific Hepatitis D Prevalence, 2016-2028
Figure 44: China, Age Specific Hepatitis D Prevalence, 2016-2028
Figure 45: China, Diagnosed cases of Hepatitis D, 2016-2028
Global Hepatitis A Vaccine Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 89
According to our LPI (LP Information) latest study, the global Hepatitis A Vaccine market size was valued at US$ 690.5 million in 2023. With growing demand in downstream market, the Hepatitis A Vaccine is forecast to a readjusted size of US$ 810.9 million by 2030 with a CAGR of 2.3% during review period.
The research report highlights the growth potential of the global Hepatitis A Vaccine market. Hepatitis A Vaccine are expected to show stable growth in the future market. However, produc......
Global Human Hepatitis B Immunoglobulin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 02-Jan-2024 Price: US 3380 Onwards Pages: 127
Market Overview of Global Human Hepatitis B Immunoglobulin market:
According to our latest research, the global Human Hepatitis B Immunoglobulin market looks promising in the next 5 years. As of 2022, the global Human Hepatitis B Immunoglobulin market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensiv......
Global Hepatitis A Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 85
According to our (Global Info Research) latest study, the global Hepatitis A Vaccine market size was valued at USD 726.3 million in 2023 and is forecast to a readjusted size of USD 842.5 million by 2030 with a CAGR of 2.1% during review period.
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
Two types of HAV vaccines are currentl......
Global Hepatitis A Vaccine Market Research Report 2024 (Status and Outlook)
Published: 15-Dec-2023 Price: US 3200 Onwards Pages: 117
Report Overview:
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
Two types of HAV vaccines are currently available internationally:
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 ye......
Global Thymosin a1 Professional Survey Report 2023, Forecast to 2028
Published: 15-Nov-2023 Price: US 3280 Onwards Pages: 103
Thymosin ?? is a peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene. It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their ......
Global Thymosin a1 Market Research Report 2023, Forecast to 2028
Published: 15-Nov-2023 Price: US 2680 Onwards Pages: 136
Thymosin ?? is a peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene. It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their ......
Global Hepatitis B Immune Globulin Market Research Report 2023
Published: 06-Nov-2023 Price: US 2900 Onwards Pages: 85
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hepatitis B Immune Globulin market with multiple angles, which provides sufficient supports to readers' strategy and decision making.
By Company
- ADMA Biologics
- Bio Products Laboratory
- Grifols
- Biotest AG
- CSL Behring
- FFF Enterprises
- Cleveland Clinic
Seg......
Global Sofosbuvir Market Research Report 2023
Published: 31-Oct-2023 Price: US 2900 Onwards Pages: 94
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Sofosbuvir market with multiple angles, which provides sufficient supports to readers' strategy and decision making.
By Company
- Teva Pharmaceutical Industries Ltd
- DONG BANG FUTURE TECH & LIFE CO., LTD
- Beaukev Pharma International Pvt.Ltd
- DEAFARMA
- Tecoland
- Anhui HaiKang Pha......
Global Hepatitis A Vaccine Market Insights, Forecast to 2029
Published: 22-Sep-2023 Price: US 4900 Onwards Pages: 97
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
Two types of HAV vaccines are currently available internationally:
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and ......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
